Try our beta test site
20 studies found for:    Open Studies | Lymphoma OR CLL | CART-19 OR Engineered Lymphocyte Therapy
Show Display Options
Rank Status Study
1 Recruiting Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)
Intervention: Biological: CART 19
Sponsor: University of Pennsylvania
Number Enrolled: 15
2 Recruiting Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
Intervention: Biological: CART-19
Sponsor: University of Pennsylvania
Number Enrolled: 57
3 Recruiting Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma
Intervention: Biological: CD19 RNA redirected autologous T-cells (RNA CART19 cells)
Sponsor/Collaborators: University of Pennsylvania;   Children's Hospital of Philadelphia
Number Enrolled: 10
4 Recruiting Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients
Intervention: Genetic: CTL019
Sponsor/Collaborators: Novartis Pharmaceuticals;   Novartis
Number Enrolled: 160
5 Recruiting CART-19 Immunotherapy in Mantle Cell Lymphoma
Intervention: Biological: anti-CD19-CAR vector-transduced T cells
Sponsor: Chinese PLA General Hospital
Number Enrolled: 2
6 Recruiting Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy
Interventions: Biological: anti-CD20-CAR vector-transduced autologous T cells;   Other: genetically engineered lymphocyte therapy
Sponsor: Chinese PLA General Hospital
Number Enrolled: 50
7 Recruiting Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19
Intervention: Biological: anti-CD19-CAR vector-transduced T cells
Sponsor: Chinese PLA General Hospital
Number Enrolled: 12
8 Recruiting Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Intervention: Biological: CART-19
Sponsor: Beijing Sanwater Biological Technology Co., Ltd.
Number Enrolled: 20
9 Recruiting A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia
Intervention: Genetic: prophylactic 4SCAR19 cells
Sponsor/Collaborators: The First People's Hospital of Yunnan;   Shenzhen Geno-Immune Medical Institute
Number Enrolled: 30
10 Recruiting The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: CART-19 cells
Sponsor/Collaborators: Henan Cancer Hospital;   The Beijing Pregene Science and Technology Company, Ltd.
Number Enrolled: 20
11 Recruiting Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
Intervention: Biological: CTL019 T-cells
Sponsor/Collaborators: Novartis Pharmaceuticals;   University of Pennsylvania;   Novartis
Number Enrolled: 67
12 Recruiting Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy
Intervention: Biological: huCART19
Sponsor: University of Pennsylvania
Number Enrolled: 50
13 Recruiting CART19 in Patient With ALL
Intervention: Biological: CART 19
Sponsor: University of Pennsylvania
Number Enrolled: 24
14 Recruiting Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia
Intervention: Biological: CART-19
Sponsor: University of Pennsylvania
Number Enrolled: 24
15 Recruiting Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies
Intervention: Biological: CD19CART
Sponsor: Innovative Cellular Therapeutics Co., Ltd.
Number Enrolled: 30
16 Recruiting CART-19 Cells For MRD Positive CD19+ ALL
Intervention: Biological: CART-19
Sponsor: Fujian Medical University
Number Enrolled: 20
17 Recruiting Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome
Interventions: Drug: Tocilizumab;   Biological: CART 19
Sponsor/Collaborators: University of Pennsylvania;   Children's Hospital of Philadelphia
Number Enrolled: 39
18 Recruiting Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes
Interventions: Drug: Cyclophosphamide or Bendamustine;   Genetic: Dose Level -1;   Genetic: Dose Level 1;   Genetic: Dose Level 2;   Genetic: Dose Level 3
Sponsor/Collaborators: Jichi Medical University;   Takara Bio Inc.
Number Enrolled: 18
19 Recruiting A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies
Intervention: Genetic: Therapeutic 4SCAR19 cells
Sponsor: Shenzhen Geno-Immune Medical Institute
Number Enrolled: 200
20 Recruiting Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes;   Other: Laboratory Biomarker Analysis
Sponsor/Collaborators: Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Number Enrolled: 169

Study has passed its completion date and status has not been verified in more than two years.